iShares Nasdaq US Biotechnology UCITS ETF

The iShares Nasdaq US Biotechnology ETF is consistently paired with core US equity trackers like SXR8 and specialized thematic funds in the technology, semiconductor, and defense sectors. In high-conviction growth portfolios, these companion assets often comprise 10 to 20 percent of the total weight, serving as aggressive return drivers that amplify portfolio volatility. Conversely, in more conservative or broadly diversified multi-asset strategies, 2B70 is relegated to a minor satellite position of 1 to 5 percent, acting as a tactical hedge or a small-cap growth tilt that provides exposure to the volatile but high-potential healthcare innovation space.

EuroFolio members primarily utilize 2B70 as a surgical instrument to capture sector-specific alpha rather than as a foundational holding. Aggressive investors, such as those behind the 2ª Iteração and Ricardo portfolios, allocate between 8 and 15 percent to the asset to capitalize on biotech cycles, accepting higher drawdowns of up to 24 percent in exchange for annualized returns exceeding 24 percent. In contrast, balanced portfolios like FINECO or 100 Aktien treat the ETF as a peripheral diversification tool, keeping allocations at or below 5 percent to mitigate the idiosyncratic risk inherent in the biotechnology sector while maintaining exposure to long-term medical advancement trends.